|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's range||2.1000 - 2.1000|
|52-week range||2.1000 - 2.8000|
|Beta (5Y monthly)||0.65|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
MILAN, September 15, 2022--Newron Pharmaceuticals today announces its half-year 2022 financial results and operational highlights and updates its R&D and business activities.
MILAN, July 01, 2022--Newron extends Senior Management team and strengthens its commitment to ESG by appointing Filippo Moriggi as Vice President of Operations.
MILAN, Italy, June 07, 2022--Newron presents encouraging interim results for evenamide in patients with Treatment-Resistant Schizophrenia (TRS). Conference call today at 9 AM ET.